#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3210	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2177	424.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1482	1482	C	432	C	361	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5040	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3996	377.6	0	.	n	.	0	T695C	SNP	695	695	T	1250	1250	C	388	C,A	332,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5040	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3996	377.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1892	1892	A	436	A	373	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5040	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3996	377.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2526	2526	C	483	C,T	408,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5040	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3996	377.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3152	3152	T	417	T	356	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5040	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3996	377.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2600	2600	A	492	A,G	412,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	500	folP	852	852	100.0	folP.l15.c4.ctg.1	1903	78.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1186	1188	AGC	111;112;112	A;G,C;C	98;96,1;97	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1148	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3818	90.1	1	SNP	p	S91F	0	.	.	271	273	TCC	805	807	TCC	109;108;108	T;C,A;C	93;93,1;90	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1148	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3818	90.1	1	SNP	p	D95G	0	.	.	283	285	GAC	817	819	GAC	106;107;107	G,A;A,C;C,A	91,1;92,1;94,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1148	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3818	90.1	1	SNP	p	D95N	0	.	.	283	285	GAC	817	819	GAC	106;107;107	G,A;A,C;C,A	91,1;92,1;94,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	498	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1651	89.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	587	589	ACC	142;143;143	A;C;C	122;125;121	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	498	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1651	89.8	0	.	p	.	0	R44H	NONSYN	130	132	CGC	602	604	CAC	140;139;139	C;A;C	120;116;118	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	498	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1651	89.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	785	787	CAC	137;138;137	C;A;C	119;120;120	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	498	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1651	89.8	1	SNP	p	G45D	0	.	.	133	135	GGC	605	607	GGC	139;140;141	G;G;C	119;119;119	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	304	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1347	67.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1030	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3246	94.7	1	SNP	p	D86N	0	.	.	256	258	GAC	791	793	GAC	123;123;125	G;A;C	104;99;107	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1030	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3246	94.7	1	SNP	p	S87R	0	.	.	259	261	AGT	794	796	AGT	125;127;127	A,C;G,T;T	102,3;108,2;110	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1030	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3246	94.7	1	SNP	p	S87W	0	.	.	259	261	AGT	794	796	AGT	125;127;127	A,C;G,T;T	102,3;108,2;110	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1030	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3246	94.7	1	SNP	p	S87I	0	.	.	259	261	AGT	794	796	AGT	125;127;127	A,C;G,T;T	102,3;108,2;110	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1030	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3246	94.7	1	SNP	p	S88P	0	.	.	262	264	TCC	797	799	TCC	127;127;127	T;C;C	111;102;110	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	888	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3166	84.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1796	1798	GGC	118;117;115	G;G;C	103;104;96	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1402	1404	GCA	133;133;134	G,A,T;C,A;A	109,2,1;115,1;115	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1405	1407	ATC	135;135;136	A;T;C	120;116;118	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1417	1419	GTG	138;137;136	G;T,G;G,T	115;115,1;116,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1417	1419	GTG	138;137;136	G;T,G;G,T	115;115,1;116,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1921	1923	ACC	90;90;89	A;C;C	76;77;72	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1975	1977	GCG	87;87;87	G;C;G	66;61;65	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1975	1977	GCG	87;87;87	G;C;G	66;61;65	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2098	2100	GGC	87;87;87	G;G;C,G	75;75;75,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2107	2109	GGC	86;86;86	G;G;C	79;75;76	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	852	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	90.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2125	2127	CCG	87;87;88	C,G;C;G	70,1;75;74	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1138	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3540	96.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1831	1833	CTG	107;108;110	C,T;T;G,C	87,1;92;91,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	602	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2188	82.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	757	757	C	99	C	88	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	578	580	GGA	138;137;137	G;G,A;A	110;114,1;115	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	0	.	p	.	0	G50N	NONSYN	148	150	GGC	584	586	AAC	137;139;140	A,G;A,G;C	117,1;119,1;119	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	839	841	CTT	105;105;106	C,G;T;T	90,1;89;87	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	863	865	GGA	107;108;109	G;G;A	88;89;94	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	0	.	p	.	0	D171G	NONSYN	511	513	GAT	947	949	GGT	113;113;112	G;G;T	98;98;97	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1001	1003	AGC	115;115;116	A,T;G;C	101,1;99;105	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1067	1067	T	110	T	94	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	1	SNP	p	G120K	0	.	.	358	360	GGT	794	796	GGT	125;123;123	G,A;G,A;T,G	104,1;101,1;100,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	1	SNP	p	A121D	0	.	.	361	363	GCC	797	799	GCC	123;123;123	G,A;C,A;C	101,1;100,1;101	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	580	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1785	95.6	1	SNP	p	A121N	0	.	.	361	363	GCC	797	799	GCC	123;123;123	G,A;C,A;C	101,1;100,1;101	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2008	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5076	118.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2126	2128	AAT	101;100;101	A;A,G;T	90;89,1;88	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	316	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1405	67.5	1	SNP	p	V57M	1	.	.	169	171	ATG	700	702	ATG	123;122;122	A;T;G	105;99;106	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
